Hydroxychloroquine Proves Ineffective in Hamsters and Macaques Infected with SARS-CoV-2
Rosenke, K.; Jarvis, M.; Feldmann, F.; Schwarz, B.; Okumura, A.; Lovaglio, J.; Saturday, G.; Hanley, P.; Meade-White, K.; Williamson, B.; Hansen, F.; Perez-Perez, L.; Leventhal, S.; Tang-Huau, T.-L.; Nason, M.; Callison, J.; Haddock, E.; Scott, D.; Sewell, G.; Bosio, C.; Hawman, D.; de Wit, E.; Feldmann, H.
Show abstract
We remain largely without effective prophylactic/therapeutic interventions for COVID-19. Although many human clinical trials are ongoing, there remains a deficiency of supportive preclinical drug efficacy studies. Here we assessed the prophylactic/therapeutic efficacy of hydroxychloroquine (HCQ), a drug of interest for COVID-19 management, in two animal models. When used for prophylaxis or treatment neither the standard human malaria dose (6.5 mg/kg) nor a high dose (50 mg/kg) of HCQ had any beneficial effect on clinical disease or SARS-CoV-2 kinetics (replication/shedding) in the Syrian hamster disease model. Similarly, HCQ prophylaxis/treatment (6.5 mg/kg) did not significantly benefit clinical outcome nor reduce SARS-CoV-2 replication/shedding in the upper and lower respiratory tract in the rhesus macaque disease model. In conclusion, our preclinical animal studies do not support the use of HCQ in prophylaxis/treatment of COVID-19.One Sentence Summary Hydroxychloroquine prophylaxis/treatment showed no beneficial effect in SARS-CoV-2 hamster and macaque disease models.Competing Interest StatementThe authors have declared no competing interest.View Full Text
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis 96%
- Enisamium reduces influenza virus shedding and improves patient recovery by inhibiting viral RNA polymerase activity 95%
- Impact of dose, duration and host immune status on ultrashort telacebec treatment in a mouse model of Buruli ulcer 95%
Similar papers in this journal
- Sex differences in lung imaging and SARS-CoV-2 antibody responses in a COVID-19 golden Syrian hamster model 95%
- The FDA-approved drug cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replication 93%
- A human-ACE2 knock-in mouse model for SARS-CoV-2 infection recapitulates respiratory disorders but avoids neurological disease associated with the transgenic K18-hACE2 model. 93%
Similar papers in this journal
- Efficacies of sequenced monotherapies of Mycobacterium avium lung infection in mouse 94%
- A bivalent Adenovirus-Vectored Vaccine induces a measurable humoral response, but does not protect cynomolgus macaques against a lethal challenge with Sudan virus 93%
- The kinetics of bedaquiline diffusion in tuberculous cavities opens a window for emergence of resistance. 93%
Similar papers in this journal
- K18-hACE2 mice develop respiratory disease resembling severe COVID-19 94%
- Post-infection treatment with the E protein inhibitor BIT225 reduces disease severity and increases survival of k18-hACE2 transgenic mice infected with a lethal dose of SARS-CoV-2 94%
- Long-term persistence of viral RNA and inflammation in the CNS of macaques exposed to aerosolized Venezuelan equine encephalitis virus. 94%
Similar papers in this journal
- The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody 93%
- Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants 93%
- Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.